Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Immunotherapeutic Targets in Non-Small Cell Lung Cancer Publisher Pubmed



Sadeghirad H1 ; Bahrami T2 ; Layeghi SM3 ; Yousefi H4 ; Rezaei M5 ; Hosseinifard SR3 ; Radfar P5 ; Warkiani ME5 ; Obyrne K6 ; Kulasinghe A1
Authors

Source: Immunology Published:2023


Abstract

Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy. © 2022 The Authors. Immunology published by John Wiley & Sons Ltd.
1. Tumor Immunology, Clinical Immunology (2022)
Experts (# of related papers)
Other Related Docs
8. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
10. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
13. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
16. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)